Cargando…
A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup
PURPOSE: There is lack of consensus on the prognostic value of received high dose intensity in osteosarcoma survivorship. Many studies have not shown a clear survival benefit when dose intensity is increased. The aim of this study is to go beyond chemotherapy intensification by arm-wide escalation o...
Autores principales: | Lancia, Carlo, Anninga, Jakob K., Sydes, Matthew R., Spitoni, Cristian, Whelan, Jeremy, Hogendoorn, Pancras C. W., Gelderblom, Hans, Fiocco, Marta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458990/ https://www.ncbi.nlm.nih.gov/pubmed/30879111 http://dx.doi.org/10.1007/s00280-019-03797-3 |
Ejemplares similares
-
Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma
por: Lancia, Carlo, et al.
Publicado: (2019) -
Marginal structural models with dose-delay joint-exposure for
assessing variations to chemotherapy intensity
por: Lancia, Carlo, et al.
Publicado: (2018) -
Disease progression in osteosarcoma: a multistate model for the EURAMOS-1 (European and American Osteosarcoma Study) randomised clinical trial
por: Hazewinkel, Audinga-Dea, et al.
Publicado: (2022) -
Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup
por: McTiernan, Anne, et al.
Publicado: (2012) -
Short-term and long-term prognostic value of histological response and intensified chemotherapy in osteosarcoma: a retrospective reanalysis of the BO06 trial
por: Musta, Eni, et al.
Publicado: (2022)